CA-MARY-KAY-INC.
20.5.2021 19:05:09 CEST | Business Wire | Press release
What started out as a way for the style community to come together when the pandemic stopped the industry in its tracks has grown into one of the largest gatherings of the fashion industry worldwide. Now, with life opening back up in the US and abroad, Glamhive ’s Digital Spring Style and Beauty Summit on May 22nd will be the final 100% digital summit. Glamhive will launch all future events as a hybrid physical-digital experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005908/en/
The Spring Summit will be the company’s fifth global digital experience and will once again bring together industry professionals and beauty and style enthusiasts to discuss spring style, skincare in the colder months, getting started in the fashion business and much more.
The all-day, ticketed event will feature 19 panels with 66-plus speakers. Below is an overview of the topics that will be covered by the all-star speaker line-up.
TOPICS:
- Who Made This? How Sustainably Sourced Products Empower Women With Every Purchase
- Style 411: Inside the World of Styling
- Contemporary Costume Design: The Role, The Challenges, And It’s Influence On Fashion
- The Red Carpet Report
- “A Star Is Born” Exclusive Interview with Astrologist Susan Miller
- Exclusive Interview with Bridgerton’s Costume Designer Ellen Mirojnick
- How To Make A Great First Impression Every Time
- Brand Building for Creatives & Entrepreneurs
During the Who Made This? How Sustainably Sourced Products Empower Women With Every Purchase panel, Chief Marketing Officer for Mary Kay Inc., Sheryl Adkins-Green, will host a discussion on the origin of the items inside each of our closets—and how we can better know the innovators behind the fashion styles. Panelists include Jane Mosbacher, Founder and CEO of TO THE MARKET; Matilda Payne Boakye-Ansah, Designer, Eco-Warrior, Social Entrepreneur, Founder of MH Couture and Co-Founder of Xtreme Upcycle; Christelle C. Paul, Founder and Director of Atelier Calla; and Tara Swennen, celebrity stylist.
“We have an opportunity every day to make choices that help protect our environment,” said Sheryl Adkins-Green, “and it’s important to know about the people and products that are making a difference.”
CO-HOSTS
Stephanie Sprangers - Founder & CEO, Glamhive
Johnny Wujek - Celebrity Stylist & Costume Designer to Katy Perry and Mariah Carey
Nicole Chavez - Celebrity Stylist to Kristen Bell and Jessica Simpson
Andrew Fitzsimons - Celebrity hairstylist to The Kardashians
Claire Sulmers - Founder + CEO of Fashion Bomb Daily
SPEAKERS:
Our speakers are celebrity stylists, makeup artists, and image-makers who work with the biggest names in Hollywood and beyond, including Kristen Stewart, Angelina Jolie, Matthew McConaughey, Emily Blunt, Gabrielle Union, Zendaya, Sophie Turner, Amanda Seyfried, Margot Robbie, Lupita Nyong’o, Emma Watson, Rosie Huntington-Whiteley, Claire Danes, Carmen Electra.
CELEBRITY STYLISTS:
Jen Rade, Tara Swennen, Jessica Paster, Nicole Chavez, Sonia Young, Dana Asher Levine, Mimi Lombardo, Joiee Thorpe, Franzy Staedter.
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Sheridan Ward, Matey Denno, Matin Maulawizada, Christian Wood, Halley Brisker, Larry Sims
MODERATORS:
Brian Underwood (Oprah Magazine), Brooke Jaffe, (Penske Media), Alexis Bennett (Vogue), Sarah Ball (PEOPLE Magazine), Flavia Nunez (Real Simple), Alana Peden (StyleCaster) and Sheryl Adkins-Green (Mary Kay Inc.)
Tickets to the conference are $149 for an all-day ticket. Presenting sponsor for the Glamhive Digital Spring Style and Beauty Summit is Mary Kay Inc. and its Mary Kay Global Design Studio.
For more information, visit https://www.glamhive.com/live
About Glamhive: Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. For stylists, it is a seamless end-to-end platform to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005908/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom